UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

On the road to optimized BTK inhibition in CLL

Blood, 2021-06, Vol.137 (24), p.3313-3314

Smolej, Lukáš

2021

Volltextzugriff (PDF)

Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle

British journal of haematology, 2020-09, Vol.190 (6), p.815-816

Smolej, Lukáš

2020

Volltextzugriff (PDF)

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

Blood, 2011-06, Vol.117 (24), p.6450-6458

2011

Volltextzugriff (PDF)

Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?

British journal of haematology, 2021-05, Vol.193 (4), p.723-726

Smolej, Lukáš

2021

Volltextzugriff (PDF)

Low‐dose fludarabine and cyclophosphamide combined with rituximab in the first‐line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long‐term results of project Q‐lite by the Czech CLL Study Group

British journal of haematology, 2021-05, Vol.193 (4), p.769-778

2021

Volltextzugriff (PDF)

External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score

British journal of haematology, 2021-04, Vol.193 (1), p.133-137

2021

Volltextzugriff (PDF)

COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group

Annals of hematology, 2023-04, Vol.102 (4), p.811-817

2023

Volltextzugriff (PDF)

Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?

Blood, 2008-09, Vol.112 (5), p.2167-2167

Smolej, Lukas

2008

Volltextzugriff (PDF)

Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab

Leukemia research, 2019-04, Vol.79, p.17-21

2019

Volltextzugriff (PDF)

Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study

Leukemia & lymphoma, 2015-07, Vol.56 (7), p.2013-2018

2015

Volltextzugriff (PDF)

Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients

British journal of haematology, 2015-07, Vol.170 (1), p.40-49

2015

Volltextzugriff (PDF)

Modern concepts in the treatment of chronic lymphocytic leukemia

Hematology (Luxembourg), 2009-10, Vol.14 (5), p.249-254

Smolej, Lukas

2009

Volltextzugriff (PDF)

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia

Leukemia research, 2012-10, Vol.36 (10), p.1278-1282

2012

Volltextzugriff (PDF)

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

Leukemia & lymphoma, 2017-02, Vol.58 (2), p.348-356

2017

Volltextzugriff (PDF)

Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy

Leukemia research, 2010-09, Vol.34 (9), p.e232-e234

2010

Volltextzugriff (PDF)

Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: Rituximab as the treatment of choice?

Leukemia research, 2007-02, Vol.31 (2), p.267-267

Smolej, Lukas

2007

Volltextzugriff (PDF)

The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab

European journal of haematology, 2013-06, Vol.90 (6), p.479-485

2013

Volltextzugriff (PDF)

Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia

Annals of hematology, 2019-12, Vol.98 (12), p.2749-2760

2019

Volltextzugriff (PDF)

COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status

Leukemia & lymphoma, 2017-01, Vol.58 (1), p.70-79

2017

Volltextzugriff (PDF)

The prognostic role of CLLU1 in chronic lymphocytic leukaemia

European journal of haematology, 2006-08, Vol.77 (2), p.177-177

Smolej, Lukas

2006

Volltextzugriff (PDF)

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study

Blood cancer journal (New York), 2019-12, Vol.9 (12), p.98-9, Article 98

2019

Volltextzugriff (PDF)

Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: Successful treatment with rituximab

Leukemia research, 2010-05, Vol.34 (5), p.e140-e141

2010

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

ThemaHematology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Humans
(27)
Male
(20)
Aged
(18)
Female
(18)
Middle Aged
(17)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(16)
Adult
(14)
Chronic Lymphocytic Leukemia
(14)
Oncology
(13)
Aged, 80 And Over
(12)
Rituximab
(11)
Leukemia
(9)
Leukemia, Lymphocytic, Chronic, B-Cell - Mortality
(9)
Prognosis
(9)
Treatment Outcome
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Antibodies, Monoclonal - Therapeutic Use
(6)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

On the road to optimized BTK inhibition in CLL

Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?

Low‐dose fludarabine and cyclophosphamide combined with rituximab in the first‐line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long‐term results of project Q‐lite by the Czech CLL Study Group

External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score

Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)

COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group

Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?

Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab

Real‐world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO‐CLLEAR Study by the Czech CLL Study Group

Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study

Ofatumumab retreatment and maintenance in fludarabine‐refractory chronic lymphocytic leukaemia patients

Modern concepts in the treatment of chronic lymphocytic leukemia

Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy

Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy

Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: Rituximab as the treatment of choice?

The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab

Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia

COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status

The prognostic role of CLLU1 in chronic lymphocytic leukaemia

Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study

Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: Successful treatment with rituximab

Aktive Filter

Suchergebnisse filtern